{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:11:12Z","timestamp":1778904672641,"version":"3.51.4"},"reference-count":8,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7475-26","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:10:56Z","timestamp":1778883056000},"source":"Crossref","is-referenced-by-count":0,"title":["Toward a Provisional Construct of \"B-cell Activated Syndrome (BCAS)\" Linking Type 1 Diabetes and Plasma Cell-rich Nephritis"],"prefix":"10.2169","author":[{"given":"Shinichiro M.","family":"Koga","sequence":"first","affiliation":[{"name":"Department of Diabetes, Endocrinology, and Metabolism, Tokyo Metropolitan Center for Cancer and Infectious Diseases Komagome Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hebisawa Y, Ohta A, Sekimoto R, et al. Plasma cell-rich nephritis with a systemic polyclonal lymphoproliferative disorder. Intern Med 64: 2747-2754, 2025.","DOI":"10.2169\/internalmedicine.4906-24"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 383: 69-82, 2014.","DOI":"10.1016\/S0140-6736(13)60591-7"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Silveira PA, Grey ST. B cells in the spotlight: innocent bystanders or major players in the pathogenesis of type 1 diabetes. Trends Endocrinol Metab 17: 128-135, 2006.","DOI":"10.1016\/j.tem.2006.03.006"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of \u03b2-cell function. N Engl J Med 361: 2143-2152, 2009.","DOI":"10.1056\/NEJMoa0904452"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 9: 491-502, 2009.","DOI":"10.1038\/nri2572"},{"key":"6","unstructured":"6. Di Lorenzo C, Sim\u00f5es C, Giannelli S, et al. Type 1 diabetes in the context of BAFF receptor deficiency and immune dysregulation. Front Immunol 13: 952715, 2022."},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. van Rhee F, Voorhees P, Dispenzieri A, et al. International evidence-based consensus diagnostic and treatment guidelines for idiopathic multicentric Castleman disease. Blood 129: 1646-1657, 2017.","DOI":"10.1182\/blood-2016-10-746933"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol 16: 448-457, 2015.","DOI":"10.1038\/ni.3153"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7475-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:27:54Z","timestamp":1778902074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7475-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":8,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7475-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7475-26"}}